See more : Ampla Energia e Serviços S.A. (CBEE3.SA) Income Statement Analysis – Financial Results
Complete financial analysis of Ultragenyx Pharmaceutical Inc. (RARE) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Ultragenyx Pharmaceutical Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Asiasoft Corporation Public Company Limited (AS.BK) Income Statement Analysis – Financial Results
- Gaekwar Mills Ltd (ZGAEKWAR.BO) Income Statement Analysis – Financial Results
- FRONTIER CAPITAL LIMITED (FRONTCAP.BO) Income Statement Analysis – Financial Results
- Athenex, Inc. (ATNX) Income Statement Analysis – Financial Results
- Workspace Group plc (WKPPF) Income Statement Analysis – Financial Results
Ultragenyx Pharmaceutical Inc. (RARE)
About Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc., Solid Biosciences Inc.; and Daiichi Sankyo Co., Ltd. Ultragenyx Pharmaceutical Inc. was incorporated in 2010 and is headquartered in Novato, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 434.25M | 363.33M | 351.41M | 271.03M | 103.71M | 51.50M | 2.61M | 133.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 45.21M | 28.32M | 16.01M | 6.13M | 9.01M | 1.15M | 1.00K | 183.20M | 1.38M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 389.04M | 335.01M | 335.40M | 264.90M | 94.71M | 50.35M | 2.61M | -183.07M | -1.38M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 89.59% | 92.21% | 95.44% | 97.74% | 91.31% | 97.77% | 99.96% | -137,647.37% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 648.45M | 705.79M | 497.15M | 412.08M | 357.36M | 294.00M | 231.64M | 183.20M | 114.74M | 45.97M | 27.83M | 12.64M | 4.72M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 127.72M | 99.91M | 64.94M | 33.00M | 10.81M | 4.45M | 3.34M | 1.84M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 309.80M | 278.14M | 219.98M | 182.93M | 161.52M | 127.72M | 99.91M | 64.94M | 33.00M | 10.81M | 4.45M | 3.34M | 1.84M |
| Other Expenses | 0.00 | 9.51M | 241.00K | 7.65M | 12.45M | 3.95M | 10.60M | 2.17M | -200.00K | -3.02M | -3.01M | -350.00K | -22.00K |
| Operating Expenses | 958.25M | 983.93M | 717.14M | 595.02M | 518.88M | 421.72M | 331.55M | 248.14M | 147.74M | 56.78M | 32.28M | 15.99M | 6.56M |
| Cost & Expenses | 1.00B | 1.01B | 733.14M | 601.15M | 527.89M | 422.87M | 331.55M | 248.14M | 147.74M | 56.78M | 32.28M | 15.99M | 6.56M |
| Interest Income | 26.69M | 11.07M | 1.93M | 7.04M | 13.24M | 9.54M | 4.07M | 3.79M | 2.32M | 608.00K | 216.00K | 1.00K | 4.00K |
| Interest Expense | 66.00M | 43.02M | 29.42M | 33.29M | 1.14M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 270.00K |
| Depreciation & Amortization | 26.01M | 18.20M | 13.24M | 12.26M | 8.54M | 19.54M | 5.83M | 3.42M | 1.38M | 684.00K | 444.00K | 313.00K | 34.00K |
| EBITDA | -516.45M | -640.51M | -410.32M | -139.81M | -389.77M | -177.56M | -312.51M | -244.58M | -146.35M | -56.09M | -34.63M | -16.02M | -6.55M |
| EBITDA Ratio | -118.93% | -175.99% | -108.56% | -118.98% | -396.98% | -1,051.94% | -12,593.49% | -186,471.43% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -569.21M | -648.92M | -381.74M | -330.12M | -424.17M | -371.37M | -328.94M | -248.01M | -147.74M | -56.78M | -32.28M | -15.99M | -6.56M |
| Operating Income Ratio | -131.08% | -178.60% | -108.63% | -121.80% | -408.98% | -721.18% | -12,593.49% | -186,471.43% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -39.26M | -52.81M | -71.24M | 144.76M | 24.73M | 174.28M | 10.60M | 2.17M | 2.12M | -3.02M | -2.79M | -349.00K | -288.00K |
| Income Before Tax | -608.46M | -701.73M | -452.98M | -185.36M | -399.44M | -197.10M | -318.34M | -245.84M | -145.62M | -59.80M | -35.07M | -16.33M | -6.85M |
| Income Before Tax Ratio | -140.12% | -193.14% | -128.91% | -68.39% | -385.14% | -382.75% | -12,187.52% | -184,841.35% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -1.83M | 5.70M | 1.04M | 1.21M | 3.28M | 514.00K | -16.20M | 35.00K | -2.32M | -684.00K | -3.01M | -350.00K | 248.00K |
| Net Income | -606.64M | -707.42M | -454.03M | -186.57M | -402.73M | -197.61M | -302.14M | -245.87M | -145.62M | -59.80M | -35.07M | -16.33M | -6.85M |
| Net Income Ratio | -139.70% | -194.71% | -129.20% | -68.84% | -388.31% | -383.75% | -11,567.34% | -184,867.67% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -8.25 | -10.12 | -6.70 | -3.07 | -7.12 | -3.97 | -7.12 | -6.21 | -3.96 | -2.08 | -1.21 | -0.71 | -0.30 |
| EPS Diluted | -8.25 | -10.12 | -6.70 | -3.07 | -7.12 | -3.97 | -7.12 | -6.21 | -3.96 | -2.08 | -1.21 | -0.71 | -0.30 |
| Weighted Avg Shares Out | 73.54M | 69.91M | 67.80M | 60.85M | 56.58M | 49.78M | 42.45M | 39.59M | 36.78M | 28.76M | 29.06M | 23.06M | 23.06M |
| Weighted Avg Shares Out (Dil) | 73.54M | 69.91M | 67.80M | 60.85M | 56.58M | 49.78M | 42.45M | 39.59M | 36.78M | 28.76M | 29.06M | 23.06M | 23.06M |
Ultragenyx Receives PRIME Designation from European Medicines Agency (EMA) for GTX-102 for the Treatment of Angelman Syndrome
Ultragenyx Announces Completion of Dosing Across Stage 1 Cohorts in Pivotal Phase 1/2/3 Cyprus2+ Study Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
After Golden Cross, Ultragenyx (RARE)'s Technical Outlook is Bright
Ultragenyx's (RARE) Preliminary 2023 Revenues Disappoint
Ultragenyx Reports Preliminary 2023 Revenue; Guidance for 2024 Revenue and Cash Usage; Pipeline Updates and 2024 Milestones
Ultragenyx (RARE) Posts Update From AS Study of GTX-102
Ultragenyx Receives Positive Recommendation from NICE in the U.K. for Evkeeza® ▼ (evinacumab) for Adolescents and Adults Aged 12 Years and Older with Homozygous Familial Hypercholesterolemia (HoFH)
Ultragenyx Announces Completion of Enrollment in Global Phase 1/2 Trial of GTX-102 in Pediatric Patients with Angelman Syndrome
Ultragenyx to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Source: https://incomestatements.info
Category: Stock Reports